中金:维持三生制药“跑赢行业”评级 上调目标价至13.50港元

智通财经网
31 Mar

智通财经APP获悉,中金发布研报称,基本维持三生制药(01530)25年经调整净利润为24.07亿元不变,引入26年经调整净利润26.02亿元。当前股价对应25/26年12.7/11.5倍经调整P/E。维持跑赢行业,由于近期港股流动性回暖和板块估值中枢上升,上调目标价68.8%至13.50港元,对应14.0/12.6倍25/26年经调整P/E,隐含9.9%上行空间。中金主要观点如下:全年业绩略超...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10